|
Results of the Zometa cost-utility model for the German healthcare system based on the results of the ABCSG-12 study |
Lux MP, Reichelt C, Wallwiener D, Kreienberg R, Jonat W, Gnant M, Beckmann MW, Thiel FC |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Lux MP, Reichelt C, Wallwiener D, Kreienberg R, Jonat W, Gnant M, Beckmann MW, Thiel FC. Results of the Zometa cost-utility model for the German healthcare system based on the results of the ABCSG-12 study. Onkologie 2010; 33(7) : 360-368 Indexing Status Subject indexing assigned by NLM MeSH Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Bone Density Conservation Agents /adverse effects /economics /therapeutic use; Breast Neoplasms /drug therapy /economics /mortality; Cost-Benefit Analysis; Diphosphonates /adverse effects /economics /therapeutic use; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Costs /statistics & Female; Germany; Goserelin /economics /therapeutic use; Humans; Imidazoles /adverse effects /economics /therapeutic use; Markov Chains; Monte Carlo Method; Multicenter Studies as Topic; National Health Programs /economics; Neoplasms, Multiple Primary /drug therapy /economics /mortality; Nitriles /economics /therapeutic use; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen /economics /therapeutic use; Triazoles /economics /therapeutic use; numerical data AccessionNumber 22010001361 Date bibliographic record published 22/12/2010 |
|
|
|